Internal Medicine, Gastroenterology · Houston, TX
NPI
1982699682
Since 2005
Specialty
Internal Medicine, Gastroenterology
Code 207RG0100X
Group practices
5
Medicare group memberships
Hospitals
1
Hospital affiliations
7737 Southwest Fwy, Suite #840
Houston, TX, 77074
Phone (713) 777-2555
Groups this clinician bills Medicare through
Medicare paid, 2024
$374K
15,985 services
Medicare patients, 2024
362
Average age 72
Drug cost, 2024
$3.6M
4,097 prescriptions
Company payments, 2025
$2,815
From 20 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Krishnamurthy Shivshanker was code 99213 (office e&m - established), 363 times for 217 patients. In total Krishnamurthy Shivshanker billed 15,985 services in 64 codes, and Medicare paid $374K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2026-04-30.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99213 Office E&M - Established | Office | 363 | 217 | $66.40 | $24K |
| 88305 Surgical Pathology Examination | Office | 355 | 101 | $27.15 | $9,637 |
| 88312 Surgical Pathology Examination | Office | 192 | 64 | $66.76 | $13K |
| 88313 Surgical Pathology Examination | Office | 189 | 64 | $55.07 | $10K |
| 99214 Office E&M - Established | Office | 135 | 92 | $90.72 | $12K |
| 43239 Upper GI Endoscopy | Facility | 84 | 80 | $79.24 | $6,656 |
| 96413 Chemotherapy Administration | Office | 59 | 14 | $101.94 | $6,015 |
| 99232 Hospital E&M - Subsequent | Facility | 59 | 39 | $61.68 | $3,639 |
| 45380 Lower GI Endoscopy - Other | Facility | 58 | 58 | $131.21 | $7,610 |
| J7050 Infusion, normal saline solution, 250 cc | Office | 57 | 15 | $0.52 | $29.43 |
| 99204 Office E&M - New | Office | 51 | 51 | $125.76 | $6,414 |
| 99203 Office E&M - New | Office | 45 | 45 | $79.62 | $3,583 |
| 45385 Colonoscopy - Lesion Removal | Facility | 19 | 19 | $211.01 | $4,009 |
| 99222 Hospital E&M - Initial | Facility | 18 | 18 | $98.54 | $1,774 |
| G0121 Colorectal cancer screening; colonoscopy on individual not meeting criteria for high risk | Facility | 17 | 17 | $184.43 | $3,135 |
By year: 2022 $272K for 10,188 services; 2023 $421K for 17,532 services; 2024 $374K for 15,985 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 88305 Surgical Pathology Examination | 355 | 101 | $27.15 | $9,637 |
| 88312 Surgical Pathology Examination | 192 | 64 | $66.76 | $13K |
| 88313 Surgical Pathology Examination | 189 | 64 | $55.07 | $10K |
Medicare prescription drug claims, 2024
In 2024, the drug Krishnamurthy Shivshanker prescribed most often to Medicare patients was Pantoprazole Sodium, with 577 prescriptions and refills. In total Krishnamurthy Shivshanker wrote 4,097 Medicare prescriptions that cost $3.6M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Pantoprazole Sodium Generic | 577 | 1,162 | 198 | $5,023 |
| Rabeprazole Sodium Generic | 399 | 808 | 122 | $15K |
| Gavilyte-G Peg3350/Sod Sulf,bicarb,cl/Kcl | 147 | 147 | 140 | $1,929 |
| Pioglitazone Hcl Generic | 134 | 253 | 45 | $1,126 |
| Ursodiol Generic | 132 | 222 | 31 | $19K |
| Colesevelam Hcl Generic | 127 | 235 | 35 | $4,797 |
| Peg 3350-Electrolyte Sodium Chloride/Nahco3/Kcl/Peg | 121 | 121 | 121 | $2,280 |
| Creon Lipase/Protease/Amylase | 108 | 135 | 29 | $238K |
| Baclofen Generic | 103 | 143 | 27 | $841 |
| Sucralfate Generic | 102 | 131 | 32 | $4,510 |
| Linzess Linaclotide | 100 | 142 | 31 | $76K |
| Budesonide Dr Budesonide | 99 | 123 | 28 | $13K |
| Dexlansoprazole Dr Dexlansoprazole | 95 | 152 | 24 | $21K |
| Omeprazole Generic | 92 | 268 | 38 | $1,621 |
| Imipramine Hcl Generic | 84 | 118 | 23 | $792 |
Brand drugs: 999 claims; generic drugs: 3,098 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Krishnamurthy Shivshanker $2,815 ($2,815 in general payments such as food, travel and fees) from 20 companies. The largest payer was Abbvie Inc. with $852.
| Company | Payments | Amount |
|---|---|---|
| Abbvie Inc. ABBV | 39 | $852 |
| Madrigal Pharmaceuticals MDGL | 43 | $579 |
| Gilead Sciences, Inc. GILD | 10 | $229 |
| Pfizer Inc. PFE | 15 | $226 |
| Takeda Pharmaceuticals U.S.A., Inc. TAK | 9 | $223 |
| Janssen Biotech, Inc. JNJ | 7 | $162 |
| Phathom Pharmaceuticals, Inc. PHAT | 1 | $121 |
| Aimmune Therapeutics, Inc. | 6 | $105 |
| Vivus LLC | 4 | $80.21 |
| Celltrion USA Inc. 068270.KS | 2 | $48.82 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.